Fresh analysis suggests that people who discontinue blockbuster GLP-1 drugs like semaglutide or tirzepatide tend to recover shed pounds much more quickly than those who halt traditional lifestyle regimens.
Research printed in a leading medical journal points out that while obese individuals can lose substantial amounts of their body weight while using the jabs, the weight comes back at an estimated rate of nearly a kilo each month once they quit.
"People purchasing these treatments should be aware of the potential of rapid rebound weight gain when the medication concludes," stated expert Dr. Susan Jebb.
That rate of recovery implies a return to original weight within about one and a half years.
Weighing Therapies
The analysis, which examined dozens of studies involving over 9,000 of patients, contrasted the results of GLP-1 agonists with conventional dieting.
Scientists note that people who shed pounds through diet and exercise typically experience a slower creep back—around 100 grams monthly—once they finish.
The Reason for the Quick Regain
Doctors believe the mode of action of the drugs explains the accelerated rebound.
The injections imitate a body's own chemical called GLP-1, which controls appetite.
"Artificially providing the hormone concentrations far above than normal might result in the system to produce less of its own natural hormone, and may also lessen responsiveness to its effects," noted Dr. Adam Collins, a nutrition researcher.
"Discontinuation of this medication leads to appetite is uncontrolled, making overeating much more probable."
An Ongoing Condition?
Medical guidelines advise the jabs for people with weight-linked medical conditions, accompanied by recommended lifestyle changes.
Many experts argue that, due to the likelihood of weight regain, the treatment might need to be ongoing.
This perspective is supported by drug manufacturers, who say that the results "underscore the chronic nature of obesity," similar to managing conditions like hypertension.
User Accounts
Users who have come off the jabs report a powerful return of cravings.
"It was like a switch flipping and I was suddenly extremely hungry," described one woman.
This challenge is worsened if users have not adopted lasting lifestyle or habit changes during treatment.
Growing Interest
Recent estimates suggest that a significant number of adults in the UK have tried these injections in the past year, with desire continuing to grow.
- Use is more common among females compared to men.
- The 40s and 50s demographic shows the greatest usage rates.
- Many access the medications through private prescriptions rather than public health services.
In conclusion, clinicians caution that while GLP-1 drugs are potent tools for weight loss, they are not a permanent solution and maintained weight loss relies on combined lifestyle support.
